GlassScriptPhysician profile
Jeffrey N Cousin
NPI 1962441022
$5,927.44
in general payments reported to CMS, 2019-2025
38 companies · $949 in 2025
The $949 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $343 · 2021: $843 · 2022: $1,113 · 2023: $1,453 · 2024: $817 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,200.16 | 2020-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $1,111.53 | 2019-2025 | |
| Genzyme Corporation | $812.05 | 2020-2025 | |
| Optinose US, INC. | $560.43 | 2019-2025 | |
| Pfizer INC. | $321.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.99 | 2022-2025 | Hyqvia, Cuvitru, Glassia |
| Alk-Abello, INC | $190.95 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $156.44 | 2022-2024 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $133.28 | 2019-2022 | |
| Grifols USA, LLC | $118.45 | 2023-2024 | Xembify |
| Regeneron Healthcare Solutions, INC. | $109.76 | 2020-2025 | Dupixent |
| Inspire Medical Systems, INC. | $89.87 | 2023-2024 | Inspire |
| Amgen INC. | $72.88 | 2021-2023 | Tezspire |
| Blueprint Medicines Corporation | $70.97 | 2023-2024 | Ayvakit |
| Csl Behring | $60.11 | 2021-2023 | Hizentra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cousin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.